Associated Genetic Biomarkers
MERTK is altered in 4.15% of all cancers with endometrial carcinoma, rectal adenocarcinoma, adenocarcinoma of unknown primary, bladder urothelial carcinoma, and cancer of unknown primary, NOS having the greatest prevalence of alterations .
The most common alterations in MERTK are MERTK Mutation (4.15%), MERTK A155T (0.30%), MERTK C361F (2.08%), MERTK E27K (2.08%), and MERTK E926A (0.30%) .
MERTK status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains MERTK status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with MERTK status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are MERTK Amplification and MERTK Mutation .
Cabozantinib is the most frequent therapy in trials with MERTK as an inclusion criteria .
Significance of MERTK in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.